The science behind every cycle.

The short versionJackson Memorial Hospital in Miami completed a six-month Extended Trial of the Medisystem H₂O₂ technology in their operating rooms with documented 91.6% bacteria reduction and extended its use across all OR suites. Independent validation by the Mario Negri Pharmacological Research Institute in Milan, the SITI public health peer-reviewed journal in Bologna, and neonatal intensive care units at Spedali Civili Brescia and Ospedale San Gerardo Monza. Two peer-reviewed scientific publications (University of Pisa, MDPI 2020; University of North Carolina, AJIC 2013) document the broader literature on hydrogen peroxide vapor disinfection. The same technology is what Blanc Estates Miami deploys today.

Jackson Memorial Hospital — Miami, Florida (2018) ⭐

In a six-month Extended Trial conducted at the operating rooms of Jackson Memorial Hospital — the largest hospital in Miami-Dade and a teaching hospital of the University of Miami Miller School of Medicine — the Medisystem H₂O₂ disinfection technology achieved a documented 91.6% reduction of bacteria on operating room surfaces. Microbiological verification was conducted in-house by the Jackson Memorial Hospital laboratory using RODAC TSA contact plates incubated at 30-35 °C for 72 hours.

The numbers

Metric	Before	After Medisystem
Plates with bacterial growth	44 (40%)	10 (9%)
Plates exceeding 3 CFU limit	29 (26.4%)	5 (3.6%)
Plates above 10 CFU (out of limits)	13 (12%)	0 (0%)

The Reference Letter

"We have completed a trial of the Medisystem, and have great results. After the 6 months Extended Trial period, using 3 Medibios units in the operating rooms, we are working to extend its use to all our operating rooms.

With the reduction of microorganisms and the reduction in the length of time for terminally cleaning the rooms this is a great benefit for the Hospital. We reduce the chances of our patient contact surgical site infection and we can further expand this to cleaning of our hospital rooms with more efficiency and less cost than the UV light system.

According the literature there is an opportunity to reduce the rate of hospital acquired infections and save us in penalties from Medicare."

— Yvette Riley, Director, PCS, Perioperative Services
Jackson Memorial Hospital, Miami, FL · June 23, 2018

Reference letter issued June 2018 following a six-month Extended Trial of the Medisystem H₂O₂ disinfection technology at Jackson Memorial Hospital. The same technology — manufactured by Amil Care Corp USA — is deployed today in Miami-Dade and Broward by Blanc Estates Miami as authorized Amil Care field partner. Healthcare-facility operations conducted under Amil Care Corp USA federal authorization.

Mario Negri Institute — Milan, Italy (2017)

The IRCCS Istituto di Ricerche Farmacologiche Mario Negri — one of the most prestigious independent pharmacological research institutes in Europe — commissioned an efficacy test of the Medisystem in its animal facility. Third-party microbiological verification was performed by ENVIGO RMS srl, a contract research laboratory.

11 sampling points were monitored, with 5 contaminated using a McFarland 0.1 (10⁶ bacteria/ml) suspension of Staphylococcus and Streptococcus. An additional point was contaminated by leaving dirty animal bedding overnight.

Sample Point	Pre-Medisystem (CFU)	Post-Medisystem (CFU)
1, 4, 8, 9	>100	0
7, 10, 11 (dirty bedding)	10-15	0
2, 3, 5, 6	1-5	0

Result: 11 of 11 sampling points returned 0 CFU after Medisystem treatment. Compliance criterion met for all points.

"The Medisystem with Medibios and Evolyse Strong can be considered as a practical and effective disinfection method with good adaptability and ease of use, and can be used with proven efficacy in areas with special sterility needs such as pharmaceutical, research and animal facility."

— Dr. Giuliano Grignaschi, Head of Animal Care Unit
IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Milan

Bologna SITI — Peer-Reviewed Publication (2011)

Researchers from the Bologna Local Health Authority (Azienda USL Bologna) and the Maggiore Hospital of Bologna conducted a controlled comparison between standard sanitization and the Medisystem H₂O₂ technology across six operating rooms. 2,176 microbiological samples were collected (2,094 surface samples + 82 air samples) over a two-week period in two ORs at the Porretta Terme Hospital and four ORs at the Maggiore Hospital of Bologna.

Findings published at the XII National Conference of Public Health, Italian Society of Hygiene, Preventive Medicine and Public Health (SITI), October 2011, by Billi, Panico, Marzola, Roncarati, Frabetti, Ucchino and Farruggia (Aziende USL of Bologna).

Microbial reduction comparison (mean % reduction, T0 vs T1):

OR Surface	Standard Protocol	Medisystem H₂O₂ + Ag⁺
Operating table	load increased	100%
Surgical lamp	load increased	99%
Ventilation grid	load increased	99.9%
Door button	load increased	100%
Center room air	90.6%	100%

The standard cleaning protocol increased microbial load on four critical OR surfaces. The Medisystem H₂O₂ technology achieved near-100% reduction across all surface categories and 100% in air quality.

Neonatal Intensive Care Units — Italy (2017-2018)

The Medisystem technology was tested in two of Italy's most sensitive hospital environments:

Ospedale San Gerardo Monza — Neonatal Intensive Care Unit (December 2017)

Test authorized by the Department Head and Head Nurse of the Neonatal ICU. Treatment with 5 ml/m³ Evolyse Strong (12% H₂O₂, 10 ppm silver), 10-minute nebulization, 60-minute dwell time.

• Incubator: 3 → 0 CFU/24 cm²
• Monitor: 7 → 0 CFU/24 cm²
• Infusion Pump: 21 → 0 CFU/24 cm²

Spedali Civili Brescia — Neonatal Intensive Care Unit (August 2018)

Two halls treated (Hall E, 150 m³; Hall C, 190 m³). Same protocol parameters.

• Incubator (Hall E): 0 → 0 (baseline)
• Monitor: 2 → 0 | Infusion Pump: 3 → 0
• Changing Table (Hall C): 2 → 0

Both studies documented 100% reduction of the microbial load still present after the normal sanification procedures.

Pathogens Documented in Validation Studies

The hydrogen peroxide vapor technology has demonstrated activity against the most clinically significant hospital-acquired infection pathogens:

Peer-Reviewed Scientific Literature

The use of hydrogen peroxide vapor for hospital surface disinfection is supported by an extensive peer-reviewed literature. Two of the most relevant references:

University of Pisa — MDPI Pathogens (2020)

Totaro M, Casini B, Profeti S, Tuvo B, Privitera G, Baggiani A. "Role of Hydrogen Peroxide Vapor (HPV) for the Disinfection of Hospital Surfaces Contaminated by Multiresistant Bacteria." Pathogens 2020, 9(5), 408. DOI: 10.3390/pathogens9050408

A systematic review of in-vitro and in-situ evidence on hydrogen peroxide vapor for MDR pathogen disinfection. Selected findings cited in the review:

• MRSA: 6 log₁₀ reduction after 30 minutes with 35% HP
• Multidrug-resistant Acinetobacter baumannii: 5.1 log₁₀ reduction
• VRE Enterococcus faecalis: 4.0 log₁₀ reduction
• Clostridium difficile spores: complete eradication in 15 minutes (30% HPV)
• Geobacillus stearothermophilus spores: full kill in 70 minutes (5-10% HP)
• HPV penetrates porous surfaces (including cotton) — a key advantage versus UV-C systems

University of North Carolina — American Journal of Infection Control (2013)

Rutala WA, Weber DJ. "Disinfectants used for environmental disinfection and new room decontamination technology." Am J Infect Control 2013;41:S36-S41. DOI: 10.1016/j.ajic.2012.11.006

• HAI burden in the US: 1.7 million infections, 99,000 deaths annually
• 20-40% of HAI are attributed to cross-infection via the hands of healthcare personnel — environmental surfaces play a critical role
• Standard manual cleaning typically achieves only 49% of surfaces (range 35-81% across 23 acute-care hospitals)
• Improved hydrogen peroxide: >6-log₁₀ reduction in 30-60 seconds
• Comparative data: HPV systems achieve complete C. difficile inactivation in situ; UV-C systems achieve 1.8-4 log reduction

Aggregate Operational Footprint

Beyond peer-reviewed studies, the Medibios + Evolyse Strong system is deployed across hospital and clinical environments in multiple countries:

• Italy — 80+ hospital and clinic deployments, including major academic medical centers and Italian National Health Service (SSN) facilities
• Mexico — Multiple private hospital and women's clinic deployments
• Dominican Republic — Operational program 2019-2024 under Equiesteril SRL, the exclusive Amil Care distributor — including premier private clinics
• United States — Jackson Memorial Hospital (Miami) Extended Trial 2018; ongoing operations in healthcare facilities, hospitality and private estates through Blanc Estates Miami as Amil Care authorized partner (Miami-Dade + Broward)

Specific facility-level data, internal validation studies and named client references are available to qualified healthcare procurement decision-makers under mutual NDA.